husCD32

husCD32 is a recombinant human soluble form of Fc gamma receptor II (CD32), designed to bind immune complexes and disrupt the interaction between IgG immune complexes and cellular Fc gamma receptors. Its mechanism of action is to competitively inhibit the binding of IgG-opsonized targets to Fc gamma receptor-expressing effector cells, thereby reducing IgG-mediated immune activation. Preclinical studies in lupus-prone NZB/NZW F1 mice demonstrated that husCD32 delays onset of proteinuria, reduces weight loss, decreases histopathological kidney findings, delays anemia, and prolongs survival, likely by intercepting immune complexes and preventing their interaction with effector cells. husCD32 did not significantly alter B cell numbers or the levels of IgG anti-dsDNA autoantibodies, nor did it significantly affect glomerular immune complex deposition. This drug represents a proof-of-concept therapeutic for systemic lupus erythematosus and potentially other immune complex-mediated diseases[1][7].

Other names

recombinant human soluble Fc gamma RIIrecombinant human soluble CD32human soluble CD32